Diagnosis of an intermediate case of maple syrup urine disease: A case report.

World J Clin Cases

Department of Genetics and Endocrinology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou 510623, Guangdong Province, China.

Published: February 2023

Background: Maple syrup urine disease (MSUD) is an autosomal recessive genetic disorder caused by defects in the catabolism of the branched-chain amino acids (BCAAs). However, the clinical and metabolic screening is limited in identifying all MSUD patients, especially those patients with mild phenotypes or are asymptomatic. This study aims to share the diagnostic experience of an intermediate MSUD case who was missed by metabolic profiling but identified by genetic analysis.

Case Summary: This study reports the diagnostic process of a boy with intermediate MSUD. The proband presented with psychomotor retardation and cerebral lesions on magnetic resonance imaging scans at 8 mo of age. Preliminary clinical and metabolic profiling did not support a specific disease. However, whole exome sequencing and subsequent Sanger sequencing at 1 year and 7 mo of age identified bi-allelic pathogenic variants of the gene, confirming the proband as having MSUD with non-classic mild phenotypes. His clinical and laboratory data were retrospectively analyzed. According to his disease course, he was classified into an intermediate form of MSUD. His management was then changed to BCAAs restriction and metabolic monitoring conforming to MSUD. In addition, genetic counseling and prenatal diagnosis were provided to his parents.

Conclusion: Our work provides diagnostic experience of an intermediate MSUD case, suggesting that a genetic analysis is important for ambiguous cases, and alerts clinicians to avoid missing patients with non-classic mild phenotypes of MSUD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979284PMC
http://dx.doi.org/10.12998/wjcc.v11.i5.1077DOI Listing

Publication Analysis

Top Keywords

mild phenotypes
12
intermediate msud
12
msud
9
maple syrup
8
syrup urine
8
urine disease
8
clinical metabolic
8
diagnostic experience
8
experience intermediate
8
msud case
8

Similar Publications

Testing for developmental toxicity is an integral part of chemical regulations. The applied tests are laborious and costly and require a large number of vertebrate test animals. To reduce animal numbers and associated costs, the zebrafish embryo was proposed as an alternative model.

View Article and Find Full Text PDF

Background: Phenotyping Alzheimer's Disease (AD) can be crucial to providing personalized treatment. Several studies have analyzed the use of digital biomarkers to characterize a subject's behavior, usually obtained from a single modality, such as speech. However, combining several modalities in a single study has not been deeply studied.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Cognitive Neuroscience Center, University of San Andrés, Victoria, Buenos Aires, Argentina.

Background: Beyond dementia syndromes, cognitive symptoms are highly prevalent in Parkinson's disease (PD), often manifesting as mild cognitive impairment (MCI). Yet, their detection and characterization remain suboptimal because standard approaches rely on subjective impressions derived from lengthy, univariate tests. Here we introduce a novel approach to detect cognitive symptom severity and identify MCI in PD using fully automated word property analyses on brief verbal fluency tasks.

View Article and Find Full Text PDF

Background: As new anti-amyloid immunotherapies emerge for Alzheimer's disease (AD), it is clear that early diagnosis of AD pathology is crucial for treatment success. This can be challenging in atypical presentations of AD and, together with our reliance on CSF or PET scans, can, at times, lead to delayed diagnosis. Here, we further explore the possible role of plasma tau phosphorylated at threonine 217 (P-tau217) for the detection of primary AD or AD co-pathology when frontotemporal dementia spectrum disorders are the main clinical presentation.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Mayo Clinic, Jacksonville, FL, USA.

Background: Two main risk factors of Alzheimer's disease (AD) are aging and APOE-ε4. However, some individuals remain cognitively normal despite having these risk factors. They are considered "cognitively resilient".

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!